5-((tert-butyldimethylsilyl)oxy)-2-hydroxybenzaldehyde | 860613-37-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-((tert-butyldimethylsilyl)oxy)-2-hydroxybenzaldehyde
• 英文别名: 5-(tert-butyldimethylsilyloxy)-2-hydroxybenzaldehyde；5-((tert-butyldimethylsilyl)oxy)salicylaldehyde；Benzaldehyde, 5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-hydroxy-；5-[tert-butyl(dimethyl)silyl]oxy-2-hydroxybenzaldehyde
• CAS: 860613-37-2
• 化学式: C₁₃H₂₀O₃Si
• 分子量: 252.386
• InChiKey: WHMCEXSSXCJIRN-UHFFFAOYSA-N

物化性质

• 沸点：
  290.8±30.0 °C(Predicted)
• 密度：
  1.043±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.59
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-((tert-butyldimethylsilyl)oxy)-2-hydroxybenzaldehyde 在 Lindlar's catalyst RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 碘苯二乙酸 、 四丁基氟化铵 、 氢气 、 sodium hexamethyldisilazane 、 乙酸酐 、 silica gel 、 copper(II) nitrate 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 苯 为溶剂， -78.0~80.0 ℃ 、101.33 kPa 条件下， 反应 4.09h， 生成 (4R,5R,6S,9S,10R,11S,16R)-11-[tert-butyl(dimethyl)silyl]oxy-6-ethyl-16-hydroxy-5-(methoxymethoxy)-4,8,10-trimethyl-2-azatetracyclo[7.6.1.02,6.012,16]hexadeca-1(15),7,12-triene-3,14-dione
  参考文献：
  名称：

  通过环过氧化[4 + 3]环化合成四氢大麻酚的四环核。

  摘要：

  DOI：

  10.1002/anie.200500247
• 作为产物：
  描述：

  2,5-bis((tert-butyldimethylsilyl)oxy)benzaldehyde 在 zinc(II) chloride 作用下， 以 1,2-二氯乙烷 为溶剂， 以61%的产率得到5-((tert-butyldimethylsilyl)oxy)-2-hydroxybenzaldehyde
  参考文献：
  名称：

  Positional chemoselectivity in the Zn(II)-mediated removal of phenol protecting groups

  摘要：

  A protocol was developed for the chemoselective ortho-deprotection of polyphenolic substrates using readily available (ZnX2)-X-II salts. This procedure provides exceptional positional selectivity for the deprotection of phenols that reside adjacent to directing carbonyl functionality in the presence of similar protecting groups at the meta and para positions. Good to excellent yields of the desired free phenols were obtained (<= 96%), and a wide assortment of protecting groups was readily removed under the reaction conditions. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.07.103

文献信息

• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• [EN] NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE<br/>[FR] NOUVEAUX COMPOSÉS PHÉNOXY CYCLIQUES ET TRAITEMENTS AMÉLIORÉS POUR UNE MALADIE CARDIAQUE ET CARDIOVASCULAIRE
  申请人：UNIV NOTTINGHAM

  公开号：WO2013121209A1

  公开（公告）日：2013-08-22

  A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: (Formula (I)) wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as hereinbelow defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituents; Z is selected from linear C2-3 alkylene; X3 is NH; R7-9 are H or substituents; their preparation and novel intermediates, compositions thereof and their use in the prevention or treatment of cardiac and cardiovascular disease and methods for the treatment thereof.

  化学式I的化合物，及其在游离形式或盐形式中的药学上可接受的盐或盐和生理水解衍生物：（化学式（I））其中Q1，CR6a和可选的R6b共同形成一个环状基团，其中：Q1选自C1-2烷基，C1-2烯基，OC1烷基和OC1烯基基团，可选择地被氧代取代；R6a是一个单键，R6b是H；或者R6a和R6b共同形成一个双键；Q2和Q3分别选自H，R1和R2；或者Q2和Q3共同形成一个环状基团，在该环状基团中，Q2和Q3中的一个是选自OC1烷基和OC1烯基基团，可选择地被氧代取代或由下文定义为R2的基团R5的环状基团，而另一个是选自C1-2烷基，C1-2烯基和OC1烷基，可选择地被氧代取代；R6a和R6b分别为H或如上定义的环状基团；Q1选自H，R1和R2以及如上定义的环状基团；R1-4为H或取代基；Z选自线性C2-3烷基；X3为NH；R7-9为H或取代基；它们的制备和新颖中间体，其组成物及其在心脏和心血管疾病的预防或治疗中的用途以及治疗方法。
• Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease
  申请人：University of Nottingham

  公开号：US20150051270A1

  公开（公告）日：2015-02-19

  A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein either Q 1 , CR 6a and optionally R 6b together form a cyclic moiety wherein: Q 1 is selected from C 1-2 alkylene, C 1-2 alkenylene, OC 1 alkylene and OC 1 alkenylene moieties optionally substituted by oxo; R 6a is a single bond and R 6b is H; or R 6a and R 6b together form a double bond; and Q 2 and Q 3 are independently selected from H, R 1 and R 2 ; or Q 2 and Q 3 together form a cyclic moiety in which one of Q 2 and Q 3 is a cyclic moiety selected from OC 1 alkylene and OC 1 alkenylene moieties optionally substituted by oxo or a group R 5 as here in below defined for R 2 and the other of Q 2 and Q 3 is a cyclic moiety selected from C 1-2 alkylene, C 1-2 alkenylene and OC 1 alkylene optionally substituted by oxo; R 6a and R 6b are each H or a cyclic moiety as defined above; and Q 1 is selected from H, R 1 and R 2 and a cyclic moiety as defined above; and R 1-4 are H or substituents; Z is selected from linear C 2-3 alkylene; X 3 is NH; R 7-9 are H or substituents; their preparation and novel intermediates, compositions thereof and their use in the prevention or treatment of cardiac and cardiovascular disease and methods for the treatment thereof.

  化学式I的化合物，及其在自由形式或盐形式中的药用可接受盐或盐和生理可水解衍生物： 其中 Q 1 ，CR 6a 和可选的R 6b 共同形成一个环状基团，其中： Q 1 选自C 1-2 烷基，C 1-2 烯基，OC 1 烷基和OC 1 烯基基团，可选择地被氧代取代； R 6a 是一个单键，R 6b 是H；或 R 6a 和R 6b 共同形成一个双键；和 Q 2 和Q 3 分别选自H，R 1 和R 2 ； 或Q 2 和Q 3 共同形成一个环状基团，在该环状基团中，Q 2 和Q 3 中的一个是选自OC 1 烷基和OC 1 烯基基团，可选择地被氧代取代或一个R 5 基团的环状基团，如下所定义的R 2 ，而另一个是选自C 1-2 烷基，C 1-2 烯基和OC 1 烷基，可选择地被氧代取代； R 6a 和R 6b 分别为H或如上定义的环状基团；和 Q 1 选自H，R 1 和R 2 以及如上定义的环状基团； 和R 1-4 为H或取代基； Z选自线性C 2-3 烷基； X 3 为NH； R 7-9 为H或取代基；它们的制备和新颖中间体，其组合物及其在预防或治疗心脏和心血管疾病中的使用以及治疗方法。
• Tandem Claisen Rearrangement/6-<i>endo</i>Cyclization Approach to Allylated and Pren­ylated Chromones
  作者：Bernd Schmidt、Martin Riemer、Uwe Schilde

  DOI：10.1002/ejoc.201501151

  日期：2015.12

  o-acylphenols reacted upon microwave irradiation to form C-allylated or -prenylated chromone derivatives, depending on the substitution pattern of the arene and the allyl substituent. The reaction proceeds through a tandem Claisen rearrangement and 6-endo-trig or 6-endo-dig cyclization sequence. For prenyl ethers, the tandem sequence can be extended by a Cope rearrangement to furnish 6-prenylchromones.

  源自邻酰基苯酚的烯丙基、二甲基烯丙基和异戊二烯醚在微波辐射下反应形成 C-烯丙基化或异戊二烯化色酮衍生物，具体取决于芳烃和烯丙基取代基的取代模式。该反应通过串联克莱森重排和 6-endo-trig 或 6-endo-dig 环化序列进行。对于异戊二烯醚，串联序列可以通过 Cope 重排扩展以提供 6-异戊二烯色酮。该方法可用于合成天然产物和药物。
• [EN] MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MCL-1 MACROCYCLIQUE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2019035927A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y的化合物，这些化合物的任何值均在规范中定义，并且其药学上可接受的盐，可用作治疗疾病和病况，包括癌症的药物。还提供了包含Formula (I)中化合物的药物组合物。